Blog
RSS FeedPosted by Michael Wonder on 26 Mar 2024
Cost and value of cancer medicines in a single payer public health system in Ontario, Canada: a cross-sectional study
26 March 2024 - We describe temporal trends in expenditure on cancer medicines within the single-payer health system of Ontario, Canada, ...
Posted by Michael Wonder on 20 Apr 2023
Rybrevant (amivantamab) receives positive CADTH reimbursement recommendation for the treatment of adult patients with non-small cell lung cancer with activating EGFR exon 20 insertion mutations
6 April 2023 - This CADTH recommendation is a step towards public access to Rybrevant as a targeted therapy for ...
Posted by Michael Wonder on 01 Nov 2022
Verzenio (abemaciclib) receives positive reimbursement recommendation from CADTH for early breast cancer
1 November 2022 - Lilly Canada announced today that CADTH has issued their final reimbursement recommendation for Verzenio (abemaciclib) in ...
Posted by Michael Wonder on 25 Oct 2022
A perspective on life cycle health technology assessment and real world evidence for precision oncology in Canada
25 October 2022 - Health technology assessment can be used to make healthcare systems more equitable and efficient. Advances in precision ...
Posted by Michael Wonder on 05 Oct 2022
Tecentriq (atezolizumab) receives CADTH reimbursement recommendations for the adjuvant treatment of early-stage non-small-cell lung cancer and the treatment of extensive stage small cell lung cancer
5 October 2022 - The CADTH recommendations are a step towards public funding of this treatment option for some patients with ...
Posted by Michael Wonder on 26 Aug 2021
AbbVie receives a positive reimbursement recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) pan-Canadian Oncology Drug Review Expert Review Committee (pERC) for Venclexta (venetoclax) in combination with azacitidine for acute myeloid leukaemia patients
26 August 2021 - pERC recommends reimbursement of Venclexta (venetoclax) in combination with azacitidine for the treatment of newly diagnosed acute ...
Posted by Michael Wonder on 04 May 2021
GSK’s Zejula is recommended for reimbursement by CADTH and INESSS for advanced ovarian cancer following response to first-line platinum-based chemotherapy
4 May 2021 - Zejula (niraparib) has received conditional positive recommendations for reimbursement from the Canadian Agency of Drugs and Technology ...
Posted by Michael Wonder on 29 Oct 2020
CADTH publishes final recommendation for Blincyto
29 October 2020 - The pERC final recommendation is based on a reconsideration of the initial recommendation and feedback from eligible ...
Posted by Michael Wonder on 13 Aug 2020
Impact of rarity on Canadian oncology health technology assessment and funding
11 August 2020 - The pan-Canadian Oncology Drug Review evaluates new cancer drugs for public funding recommendations. ...
Posted by Michael Wonder on 12 May 2020
Evaluation of the impact of patient involvement in health technology assessments: a scoping review
8 May 2020 - While involving patients in health technology assessment has become increasingly common and important around the world, little ...
Posted by Michael Wonder on 23 Sep 2019
Health‐related quality of life in oncology drug reimbursement submissions in Canada: a review of submissions to the pan‐Canadian Oncology Drug Review
23 September 2019 - In Canada, CADTH evaluates and makes recommendations for the reimbursement of cancer drugs. One component of ...
Posted by Michael Wonder on 21 Jan 2019
Will price be a barrier to new cancer immunotherapy?
19 January 2019 - Advisory group CADTH recommends no funding for new CAR-T therapy until drug company lowers cost. ...
Posted by Michael Wonder on 17 Jan 2019
Gene therapy drug Kymriah should be publicly covered if manufacturer drops price, report recommends
16 January 2019 - A groundbreaking gene therapy for cancer could cost the Canadian health care system more than $400 ...
Posted by Michael Wonder on 05 Nov 2018
CADTH publishes initial recommendation for Tagrisso
5 November 2018 - CADTH has published its initial recommendation on the use of osimertinib mesylate for the first-line treatment ...
Posted by Michael Wonder on 05 Nov 2018
CADTH publishes initial recommendation for Lenvima
5 November 2018 - CADTH has published its initial recommendation on the use of lenvatinib mesylate in combination with everolimus ...